NuGen Medical Devices Inc.
NGMD.V
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 139.68% | 57.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 139.68% | 57.50% | |||
| Cost of Revenue | 272.45% | 53.13% | |||
| Gross Profit | 56.21% | 59.38% | |||
| SG&A Expenses | -16.58% | 44.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.69% | 21.65% | |||
| Operating Income | 1.29% | -20.85% | |||
| Income Before Tax | -171.87% | 19.09% | |||
| Income Tax Expenses | 1,154.55% | -210.00% | |||
| Earnings from Continuing Operations | -175.10% | 19.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -175.10% | 19.43% | |||
| EBIT | 1.29% | -20.85% | |||
| EBITDA | 4.26% | -24.18% | |||
| EPS Basic | -173.33% | 18.92% | |||
| Normalized Basic EPS | -143.24% | 19.57% | |||
| EPS Diluted | -173.33% | 18.92% | |||
| Normalized Diluted EPS | -143.24% | 19.57% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||